The Gentian Cystatin C Immunoassay is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro diagnostic testing of cystatin C in human plasma and serum samples. The assay is rapidly performed in only 10 minutes and can be applied on a wide range of clinical chemical analysers. Through the incorporation of avian antibodies (IgY), the immunoturbidimetric assay is highly sensitive and with lower interference relative to market alternatives.
Cystatin C correlates closely with the mGFR, and cystatin C testing can therefore improve patient treatment. Cystatin C based drug-specific dosing protocols are beneficial in treatment with prescribed medications that are renally eliminated and/or nephrotoxic. Correct dosing can create cost savings, due to more effective treatment and shorter recovery time.
The estimated GFR is more accurate if both cystatin C and creatinine are measured and used to calculate the eGFR. In the presence of confounding factors related to muscle mass such as age, protein intake, gender and ethnicity, the KDIGO guidelines recommend using cystatin C to calculate eGFR or direct measurement of GFR when precision is required (KDIGO Guidelines 2012).
Want to know more about Gentian’s cystatin C immunoassay? Watch this webinar with Gentian’s Product Manager for cystatin C, Gaute Tangen. He goes into details about the immunoassay’s advantages.